NO20091419L - Fenyleddiksyrederivat - Google Patents
FenyleddiksyrederivatInfo
- Publication number
- NO20091419L NO20091419L NO20091419A NO20091419A NO20091419L NO 20091419 L NO20091419 L NO 20091419L NO 20091419 A NO20091419 A NO 20091419A NO 20091419 A NO20091419 A NO 20091419A NO 20091419 L NO20091419 L NO 20091419L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkyl
- hydrogen atom
- halogen
- alkoxyl
- Prior art date
Links
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- -1 nitro, cyano, hydroxy, amino Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
- C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Forbindelse med forrnel (1) eller et salt derav som har en overlegen inhiberende virkning på produksjonen av prostaglandin E2 og er anvendelig som en aktiv ingrediens i et farmasøytisk middel med reduserte bivirkninger, så som gastrointestinale forstyrrelser, hvor ---- representerer enkeltbinding eller dobbeltbinding; W er hydrogenatom eller alkylgruppe; R2 og R3 er hydrogenatom eller alkylgruppe; R4 og R5 er hydrogenatom, hydroksygruppe, alkoksylgruppe, halogen eller mono- eller di-alkylsubstituert aminogruppe; R6 er hydrogenatom, cyanogruppe, alkoksykarbonylgruppe eller karboksygruppe; R7 representerer én eller to substituenter på benzenringen, valgt blant hydrogen, halogen, nitro, cyano, hydroksy, amino, alkyl og alkoksyl, A representerer en 5- eller 6-leddet heterosyklisk ring som inneholder ett eller to tilgrensende svovelatomer som uavhengig av til hverandre kan danne oksid, W---- representerer en oksogruppe, hydrogen, alkyl, hydroksy, alkoksyl eller halogen, og X representerer oksygen eller svovel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006245194 | 2006-09-11 | ||
| PCT/JP2007/067568 WO2008032665A1 (en) | 2006-09-11 | 2007-09-10 | Novel phenylacetic acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091419L true NO20091419L (no) | 2009-05-20 |
Family
ID=39183724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091419A NO20091419L (no) | 2006-09-11 | 2009-04-07 | Fenyleddiksyrederivat |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8148421B2 (no) |
| EP (1) | EP2062884B1 (no) |
| JP (1) | JP4538072B2 (no) |
| KR (1) | KR101360579B1 (no) |
| CN (1) | CN101535289B (no) |
| AR (1) | AR062723A1 (no) |
| AU (1) | AU2007295510B2 (no) |
| BR (1) | BRPI0716550A2 (no) |
| CA (1) | CA2663234C (no) |
| ES (1) | ES2402377T3 (no) |
| IL (1) | IL197506A0 (no) |
| IN (1) | IN2009CN01906A (no) |
| MX (1) | MX2009002692A (no) |
| NO (1) | NO20091419L (no) |
| NZ (1) | NZ575635A (no) |
| RU (1) | RU2414465C2 (no) |
| TW (1) | TW200827343A (no) |
| WO (1) | WO2008032665A1 (no) |
| ZA (1) | ZA200901988B (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101704777B (zh) * | 2009-10-18 | 2012-10-31 | 伊泰(北京)合成技术有限公司 | 一种去除前列素类化合物5，6位反式双键异构体的方法 |
| CN116239498B (zh) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | 制备克立硼罗中间体的方法 |
| CN116253756B (zh) * | 2023-05-11 | 2023-07-18 | 北京元延医药科技股份有限公司 | 克立硼罗的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161538A (en) | 1977-04-05 | 1979-07-17 | Sankyo Company Limited | Substituted phenylacetic acid derivatives and process for the preparation thereof |
| JPS5432460A (en) | 1977-08-16 | 1979-03-09 | Sankyo Co Ltd | Cycloalkylidenemethylphenylacetic acid derivative and their preparation |
| JPS5461159A (en) * | 1977-10-21 | 1979-05-17 | Sagami Chem Res Center | Alpha-thio-alpha-(acylphenyl) carboxylic acid derivatives |
| JPS5481260A (en) | 1977-11-21 | 1979-06-28 | Toyama Chem Co Ltd | 2-4-(3-methyl-2-thienyl)phenyl propionic acid, its nontoxic salt and antiphlogistics, analgesics, and antirheumatics containing them |
| JPS6019909B2 (ja) * | 1980-05-08 | 1985-05-18 | 富山化学工業株式会社 | ２―〔４―（３―メチル―２―チエニル）フエニル〕プロピオン酸及びその非毒性塩 |
| JPS58105939A (ja) * | 1981-12-18 | 1983-06-24 | Sankyo Co Ltd | 置換フエニル酢酸誘導体及びその製法 |
| EP0641760B1 (en) * | 1991-08-10 | 1996-11-06 | Hisamitsu Pharmaceutical Co., Inc. | Phenylalkanoic acid derivative, production thereof, and separation of optical isomers thereof |
| JPH05132478A (ja) * | 1991-11-11 | 1993-05-28 | Hisamitsu Pharmaceut Co Inc | 新規な（１，３−ジチオラン−２−イリデン）メチル フエニルアルカン酸誘導体 |
| AU4481600A (en) | 1999-04-22 | 2000-11-10 | Qode.Com, Inc. | System and method for providing electronic information upon receipt of a scannedbar code |
| WO2001014349A1 (en) * | 1999-08-23 | 2001-03-01 | Kyorin Pharmaceutical Co., Ltd. | Substituted benzylthiazolidine-2,4-dione derivatives |
| CA2405170A1 (en) * | 2000-04-24 | 2001-11-01 | Merck Frosst Canada & Co. | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
| WO2004028535A1 (en) | 2002-09-26 | 2004-04-08 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
-
2007
- 2007-09-07 TW TW096133551A patent/TW200827343A/zh unknown
- 2007-09-10 CN CN2007800337348A patent/CN101535289B/zh not_active Expired - Fee Related
- 2007-09-10 RU RU2009113546/04A patent/RU2414465C2/ru not_active IP Right Cessation
- 2007-09-10 BR BRPI0716550-1A2A patent/BRPI0716550A2/pt not_active IP Right Cessation
- 2007-09-10 JP JP2008534321A patent/JP4538072B2/ja not_active Expired - Fee Related
- 2007-09-10 KR KR1020097007100A patent/KR101360579B1/ko not_active Expired - Fee Related
- 2007-09-10 NZ NZ575635A patent/NZ575635A/en not_active IP Right Cessation
- 2007-09-10 EP EP07828211A patent/EP2062884B1/en not_active Not-in-force
- 2007-09-10 WO PCT/JP2007/067568 patent/WO2008032665A1/ja not_active Ceased
- 2007-09-10 AR ARP070103987A patent/AR062723A1/es not_active Application Discontinuation
- 2007-09-10 ES ES07828211T patent/ES2402377T3/es active Active
- 2007-09-10 IN IN1906CHN2009 patent/IN2009CN01906A/en unknown
- 2007-09-10 AU AU2007295510A patent/AU2007295510B2/en not_active Ceased
- 2007-09-10 ZA ZA200901988A patent/ZA200901988B/xx unknown
- 2007-09-10 US US12/440,540 patent/US8148421B2/en not_active Expired - Fee Related
- 2007-09-10 MX MX2009002692A patent/MX2009002692A/es active IP Right Grant
- 2007-09-10 CA CA2663234A patent/CA2663234C/en not_active Expired - Fee Related
-
2009
- 2009-03-10 IL IL197506A patent/IL197506A0/en unknown
- 2009-04-07 NO NO20091419A patent/NO20091419L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100048666A1 (en) | 2010-02-25 |
| AU2007295510A1 (en) | 2008-03-20 |
| TW200827343A (en) | 2008-07-01 |
| RU2009113546A (ru) | 2010-10-20 |
| IN2009CN01906A (no) | 2015-08-07 |
| CA2663234C (en) | 2014-08-05 |
| EP2062884A4 (en) | 2011-11-09 |
| KR20090061034A (ko) | 2009-06-15 |
| CN101535289B (zh) | 2013-06-05 |
| ZA200901988B (en) | 2010-06-30 |
| IL197506A0 (en) | 2009-12-24 |
| BRPI0716550A2 (pt) | 2013-09-24 |
| CN101535289A (zh) | 2009-09-16 |
| EP2062884A1 (en) | 2009-05-27 |
| ES2402377T3 (es) | 2013-05-03 |
| NZ575635A (en) | 2011-08-26 |
| AU2007295510B2 (en) | 2011-09-01 |
| MX2009002692A (es) | 2009-03-30 |
| EP2062884B1 (en) | 2013-02-20 |
| JP4538072B2 (ja) | 2010-09-08 |
| JPWO2008032665A1 (ja) | 2010-01-28 |
| AR062723A1 (es) | 2008-11-26 |
| CA2663234A1 (en) | 2008-03-20 |
| KR101360579B1 (ko) | 2014-02-10 |
| WO2008032665A1 (en) | 2008-03-20 |
| RU2414465C2 (ru) | 2011-03-20 |
| US8148421B2 (en) | 2012-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4282486A3 (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| MX2010005299A (es) | Derivados de bis-(sulfonilamino) en terapia 066. | |
| NO20070249L (no) | Pyrrazolo-pyrimidin derivater | |
| NO20090835L (no) | Nye HIV-reverstranskriptaseinhibitorer | |
| NO20083669L (no) | 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav | |
| NO20081892L (no) | Polycykliske karbamoylpyridonderivat med HIV-integraseinhiberende aktivitet | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| NO20081464L (no) | 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| JO3259B1 (ar) | مشتق دائري مغاير ملتحم واستخدامه | |
| NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| NO20076006L (no) | Acetylenderivater | |
| MX2010004293A (es) | Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet. | |
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| NO20084516L (no) | Terfenylderivater for behandling av alzheimers sykdom | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| TW200602319A (en) | Indole derivative and use thereof | |
| NO20063821L (no) | Kinolinderivater for anvendelse som mykobakterielle inhibitorer | |
| NO20085107L (no) | Spirosykliske nitriler som proteaseinhibitorer | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| MX2009010302A (es) | Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |